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therapeutic potential of CD133þprogenitor cellsJian Guo, MD, PhD, Ren-Ke Li, MD, PhD, and Richard D. Weisel, MDCell therapy promised to regenerate the heart after a myocar-
dial infarction (MI). Indeed, preclinical studies demon-
strated dramatic improvements in ventricular function after
cells of various types were implanted into the damaged myo-
cardium; however, cell therapy was less effective in the ini-
tial clinical trials. Investigators have thus returned to the
bench to identify new approaches to stem cell therapy that
can be used at the bedside. In this issue of the Journal, Zhang
and colleagues1 report a new approach to expand the number
of enriched progenitor cells (CD133þ/CD34þ/VEGFR-2þ
cells) for implantation and produce more extensive angio-
genesis in the ischemic myocardium. The second generation
of cell therapies may finally achieve myocardial regenera-
tion. This editorial reviews the results of the initial clinical
trials, the potential benefits of expanded marrow stem cells,
and the challenges facing cell therapy.CLINICAL TRIALS OF CELL THERAPY
Schachinger and colleagues2 reported that infusing bone
marrow progenitor cells 3 to 7 days after reperfusion of an
MI improved global and regional ventricular function. Cell
therapy was associated with a decrease in end-systolic vol-
umes and a 5% increase in ejection fraction (EF) in patients
with baseline dysfunction. Meta-analyses3 demonstrated
that most clinical trials reported a similar statistically signif-
icant increase in EF that was smaller than that reported in the
preclinical studies. However, stem cell therapy not only in-
duced angiogenesis but also inhibited matrix degradation
(which prevented ventricular dilatation) and recruited resi-
dent stem cells (which stimulated infarct healing).4,5 There-
fore, cell therapy produced more extensive beneficial effects
on infarct size and ventricular volume than on EF.
The clinical impact of cell therapy deserves careful atten-
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The Journal of Thoracic and Carpatients randomized to progenitor cell therapy had fewer
deaths or MIs and required fewer revascularization proce-
dures (20%) compared with the placebo group (40%). In
the BALANCE trial,6 implanted bone marrow cells reduced
infarct size and ventricular volumes and increased EF, but
also improved survival at 4.6 years. A recent comparative
analysis7 demonstrated that the beneficial effects associated
with cell implantation were similar to the established effects
of reperfusion (stenting), beta-blockers, and angiotensin-
converting enzyme inhibitors after an MI. The authors con-
cluded their evaluation ‘‘reveals that improvements in EF
achieved by cell therapy are within an intriguingly similar
range compared with established therapeutic strategies.’’
Although many scientists were disappointed with the results
of the initial clinical trials, cell therapy offers significant
advantages over other approaches to prevent heart failure
after an MI.
ENHANCEDANGIOGENESISWITH CD133þCELLS
The CD133þ fraction of the bone marrow contains hema-
topoietic stem cells and endothelial progenitor cells, and is
therefore an excellent source of candidate cells for cell ther-
apy. Implanted CD133þcells survived in the infarcted myo-
cardium, inducing angiogenesis and supporting functional
recovery. Injecting these cells into the infarct region during
coronary artery bypass grafting significantly improved ven-
tricular function at 6 months.8 Unfortunately, the clinical
utility of CD133þ cells has been hampered by the limited
number that can be isolated from patients with heart failure,
who are most likely to benefit from cell therapy.9
Zhang and colleagues1 describe innovative methods to in-
crease the number of CD133þ/CD34þ/VEGFR-2þprogenitor
cells available from the pool of mononuclear cells. The
expanded cells retained their angiogenic capacity, but the
mechanisms responsible were not fully elucidated. Future
studies will be required to determine which genes are
expressed when CD133þ cells evolve from the pool of
CD133- cells. Genome-wide profiling may also help deter-
mine how these stem cells induce angiogenesis through
paracrine signaling. Why do CD133þcells inhibit the gener-
ation of new CD133þ cells? Do the CD133þ cells secrete
soluble factors that inhibit CD133 gene expression via an au-
tocrine feedback loop?
The most interesting aspect of the study by Zhang and col-
leagues1 is the finding that the induction of angiogenesis by
CD133þ cells exceeded that by mesenchymal stromal cells
(MSCs), which are the other stem cells found in the bone
marrow mixture that was used in the initial clinical trials.2,3diovascular Surgery c Volume 139, Number 6 1369
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supports the in vivo results of Mathieu and colleagues,10
who also demonstrated that a bone marrow mixture enriched
for hematopoietic precursors induced more angiogenesis
than MSCs in a canine model of MI. However, although
the CD133þ fraction may induce more angiogenesis than
MSCs, stromal cells also alter matrix remodeling, reduce
ventricular volumes, and recruit autologous stem cells.11
In addition, MSCs can be expanded in vitro, and their para-
crine effects can be enhanced through gene transfection.12
Gene-transfected MSCs have been demonstrated to boost
angiogenesis, reverse matrix remodelling, and increase the
recruitment of recipient stem cells. Extensive large animal
and clinical trials will be necessary to determine which
cell mixture best restores ventricular function after an MI.CHALLENGES ASSOCIATED WITH CELL
THERAPY
The main obstacle to the success of clinical cell therapy is
the limited regenerative capacity of stem cells from aging
patients with extensive comorbidities (eg, diabetes and ex-
tensive atherosclerosis). The present challenge is to rejuve-
nate these stem cells. Preconditioning is known to improve
the survival and engraftment of bone marrow stem cells.
However, reestablishing the paracrine capacity of either
bone marrow cells or the CD133þ fraction might not be
possible in elderly patients. In that case, the restoration of
ventricular function may be best achieved with allogeneic
MSCs (from young, healthy adults) that may avoid rejection
after implantation.13CONCLUSIONS
Cell therapy continues to offer the promise to restore car-
diac function after an MI. Informed by the results of the ini-
tial clinical trials, investigators have returned to the bench to
develop new approaches. The unique method reported by
Zhang and colleagues1 to expand the stem cell-containing
bone marrow fraction may expand the clinical utility of
cell therapy. In the future, additional modifications may
not only induce angiogenesis but also achieve infarct healing1370 The Journal of Thoracic and Cardiovascular Surin the hearts of elderly patients who are at the greatest risk of
heart failure.
We thank Heather McDonald Kinkaid for editorial assistance.
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